Drug
Ponesimod
Ponesimod: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ponesimod NCT07686081 | Phase 3 | Ulcerative Colitis (UC) |
| Ponesimod NCT07362017 | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis |
Latest
No recent events.
Follow Ponesimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.